Actelion: FV upgrade ahead of FDA's decision on Opsumit

BUY, Fair Value CHF73 vs. CHF67 (+15%)

News published on October Friday 18, 2013
Share on

After a surprising share price drop yesterday, we are reiterating our BUY rating on Actelion ahead of the expected approval of Opsumit by next Monday. Despite unknowns about label and pricing that could impact the ramp-up of the drug, we feel reasonably confident when considering the overall data package. However beyond small adjustments to our numbers following Q3 results and the new number of shares retained for calculation, we are opportunistically including Ceptaris in our model for the first time, thereby adding CHF2/share to our FV. Although we do not underestimate execution risks related to Opsumit (label, price, penetration rate, impact on Tracleer …), we believe that the exciting and eventful times ahead should boost the share price further. Hence our BUY rating with a new FV.


Full report available to subscribers
Please contact marketing@bryangarnier.fr  

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities